Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab.

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

Earlier this week, Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab. Merck was separately studying vibostolimab and ...